Vincristine Sulfate: The Microtubule-Concentrating on Chemotherapy Agent Revolutionizing Oncology | Supplier & Manufacturer
1. What is Vincristine?
Vincristine sulfate is a dimeric Catharanthus alkaloid derived from the Madagascar periwinkle (Catharanthus roseus). As a microtubule-disrupting agent, it binds with excessive affinity to β-tubulin on the vinca area, inhibiting microtubule polymerization and disrupting mitotic spindle meeting. This triggers metaphase arrest y apoptosis in quickly dividing cells. Labeled as a WHO Important Medication, it is clinically indispensable for treating acute leukemias, lymphomas, and strong tumors via its potent antimitotic exercise.
2. Suministro, propiedades químicas e identificadores
-
Suministrar: Remoted from Catharanthus roseus leaves; semi-synthesized from precursors catharanthine and vindoline
-
Propiedades químicas:
-
Nombre químico: Methyl (2β,3β,4β,5α,12β,19α)-15-[(5S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate sulfate
-
Método molecular: C₄₆H₅₆N₄O₁₀·H₂SO₄
-
Peso molecular: 923.04 g/mol
-
Apariencia: White to off-white hygroscopic powder
-
Solubilidad: Freely soluble in water (30 mg/mL), sparingly soluble in ethanol
-
Estabilidad: Gentle-sensitive; degrades above pH 5.5
-
-
Identificadores clave:
-
CAS: 2068-78-2 (vincristine sulfate)
-
Cantidad CE (EINECS): 218-216-0
-
MF: C₄₆H₅₈N₄O₁₄S
-
MW: 923.04
-
3. Pharmaceutical-Grade Specs & Scientific Profile
-
Optimum Product: Requires >99.5% HPLC purity, <0.1% vinblastine (poisonous analog), and endotoxin-free (<0.25 EU/mg). Shaanxi Zhonghong achieves this via countercurrent chromatography y lyophilization stabilization.
-
Therapeutic Purposes:
-
Oncología: First-line for ALL (induction remedy), Hodgkin/non-Hodgkin lymphoma, neuroblastoma, Wilm’s tumor
-
Mecanismo: Binds tubulin dimer (Kd=85 nM) → suppresses microtubule dynamics → mitotic disaster
-
(Observe: Nattokinase demonstrates fibrinolytic exercise; no medical proof helps nephroprotective advantages)
-
-
Dosificación:
-
IV Administration Solely: 1.4-2.0 mg/m² weekly (max 2 mg/dose)
-
No oral bioavailability; by no means self-administer
-
-
Crucial Security Profile:
-
Neurotoxicity: Dose-limiting peripheral neuropathy (sensory > motor)
-
Hematologic: Delicate myelosuppression (in contrast to vinblastine)
-
Autonomic Results: Ileus, bladder atony, orthostatic hypotension
-
Extravasation Threat: Extreme tissue necrosis requiring central line
-
Contraindicaciones: Charcot-Marie-Tooth illness, intrathecal administration (deadly)
-
4. Shaanxi Zhonghong: cGMP Vinca Alkaloid Specialist
Con 28+ years in plant-derived oncology APIs, we produce EP/USP-compliant vincristine sulfate:
-
Scientific Infrastructure:
-
5 College Joint Labs (Tubulin binding analysis)
-
Patented Tech: CN202310XXXXXX (Vindoline stabilization)
-
-
Capacidades analíticas:
-
UPLC-MS/MS (purity/impurities)
-
600MHz NMR (structural affirmation)
-
ICP-MS (elemental impurities)
-
LAL Chromogenic (endotoxins)
-
-
World Distribution: API shipments to Más de 80 países with cold-chain compliance
5. Pharmaceutical High quality Specs
Clase | Parámetro | Especificación | Técnica |
---|---|---|---|
pesticidas | Clorpirifos | ≤0,01 mg/kg | GC-MS/MS |
Dimethoate | ≤0.02 mg/kg | LC-MS/MS | |
Metales pesados | Pb | ≤1,0 ppm | ICP-MS (USP <232>) |
Cd | ≤0,5 ppm | ICP-MS | |
Microbiología | TAMC | ≤10² CFU/g | USP <61> |
E. coli | Ausente/10g | USP <62> | |
Crucial Attributes | Vincristine Sulfate | ≥99,5% | HPLC-PDA (USP <621>) |
Vinblastina | ≤0,1% | UPLC-MS | |
Water Content | ≤4.0% | Karl Fischer | |
Endotoxinas | <0,25 UE/mg | LAL (USP <85>) |
6. cGMP Manufacturing Course of
-
Abastecimiento botánico: C. roseus cultivated underneath GACP tips
-
Alkaloid Extraction: Ethanol/water gradient extraction (pH 4.0)
-
Precursor Isolation: Cromatografía de intercambio iónico (vindoline)
-
Oxidative Coupling: Fe³⁺/H₂O₂-mediated dimerization
-
Sulfation: Response with SO₃-pyridine complicated
-
Cristalización: Managed polymorph formation (Type II crystals)
-
Liofilización: -50°C freeze-drying underneath nitrogen environment
-
Filtración estéril: 0.22 µm membrane filtration
7. Scientific & Analysis Purposes
-
Oncology Protocols:
-
R-CHOP (lymphoma)
-
VDCLP (pediatric ALL)
-
-
Métodos de suministro de medicamentos:
-
Liposomal encapsulation (Marqibo®)
-
Peptide-drug conjugates (tumor-targeted supply)
-
-
Neuroscience Analysis:
-
Axonal transport research
-
Neurotoxicity modeling
-
8. cGMP High quality Management Protocol
Zhonghong’s 360° QC consists of:
-
Identificación: ¹³C NMR (C-18/C-19 carbonyl resonance at 175.2 ppm)
-
Pureza: HPLC-ELSD quantifies vincristine (≥99.5%) and vinblastine (≤0.1%)
-
Efficiency: Tubulin polymerization assay (IC₅₀ 0.1-0.3 μM)
-
Security: Bacterial endotoxins (kinetic chromogenic LAL), sterility testing (USP <71>)
-
Estabilidad: 24-month shelf-life at 2-8°C (ICH Q1A validated)
9. Chilly-Chain Packaging & Logistics
-
Main Container: Sort I amber vials (nitrogen headspace)
-
Embalaje secundario: Vacuum-sealed Alu-PET pouches with desiccant
-
Almacenamiento: 2-8°C shielded from gentle
-
Delivery: World cold-chain transport (2-8°C) by way of DHL Thermonet
10. Mechanism & Improvements
-
Molecular Motion:
-
Excessive-affinity binding to βIII-tubulin isotype
-
Suppresses microtubule dynamic instability by 95%
-
Induce Bim-mediated apoptosis
-
-
Zhonghong Improvements:
-
Enzymatic dimerization (yield ↑35%)
-
Cryogenic milling for particle dimension management
-
-
Fronteras del análisis:
-
Tubulin isotype-specific analogs
-
Neuroprotective co-administration (glutamate antagonists)
-
-
Desafíos:
-
Neurotoxicity administration
-
ABC transporter-mediated resistance
-
11. Preguntas frecuentes
Q1: Can vincristine be used as a dietary complement?
A: Completely not. Vincristine is a cytotoxic chemotherapy agent requiring medical supervision. Unauthorized use causes extreme neurotoxicity.
Q2: Does nattokinase profit kidney sufferers?
*A: No medical proof helps nattokinase for kidney illness. Vincristine requires dose adjustment in renal impairment (CrCl <30 mL/min).*
Q3: Why is vinblastine impurity managed?
*A: Vinblastine causes distinct myelotoxicity. Our UPLC-MS detects ≤0.05% impurity (ICH Q3A limits).*
This autumn: What distinguishes Zhonghong’s vincristine?
*A: cGMP manufacturing, ≥99.5% purity, endotoxin management (<0.25 EU/mg), and patented lyophilization expertise.*
Q5: Do you provide vincristine for ADCs?
*A: Sure. GMP-grade maleimide-activated vincristine accessible for antibody-drug conjugates (DAR 4-8).*
12. World Procurement
Supply cGMP vincristine sulfate:
✉️ Correo electrónico: liaodaohai@gmail.com
🌐 Neto: www.aiherba.com
Request: COA, DMF, regulatory help, and customized synthesis choices.
13. Conclusión
Vincristine sulfate stays a cornerstone of pediatric and hematologic oncology with distinctive microtubule-targeting properties. Its medical utility is dependent upon pureza ultraalta (>99,5%), stringent neurotoxic impurity management, y temperature-managed distribution. Shaanxi Zhonghong combines three many years of vinca alkaloid experience, patented stabilization expertise, y Cumplimiento de las normas cGMP to ship APIs assembly international pharmacopeial requirements. Associate with us for uncompromising high quality in most cancers therapeutics.
14. Referencias
-
Noble RL, et al. (1958). Sociedad Química Americana. 80:3487. [DOI:10.1021/ja01546a092]
-
Jordan MA, et al. (1985). J Biol Chem. 260:14608. [PMID:2995464]
-
WHO EML (2023): Vincristine sulfate injection
-
USP Monograph: Vincristine Sulfate. USP44-NF39
-
EMA Guideline CPMP/QWP/1850/04
-
Lobert S, et al. (1996). Biochemistry. 35:6806. [DOI:10.1021/bi952483n]
-
Zhonghong Patent: CN202310XXXXXX (Cryo-milling course of)
-
ICH Q3D (R2): Elemental Impurities
-
FDA Label: Vincristine Sulfate Injection
-
Gidding CEM, et al. (1999). Most cancers Chemother Pharmacol. 44:266. [DOI:10.1007/s002800050976]
Valoraciones
No hay valoraciones aún.